KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $96000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) changed 0.0% year-over-year to $96000.0, compared with a TTM value of $387000.0 through Sep 2025, down 63.0%, and an annual FY2024 reading of $509000.0, down 44.79% over the prior year.
  • Depreciation & Amortization (CF) was $96000.0 for Q3 2025 at TherapeuticsMD, roughly flat from $96000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.0 million in Q2 2021 and bottomed at -$2.4 million in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $192000.0, with a median of $133000.0 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) tumbled 329.09% in 2021, then soared 392.59% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at -$2.4 million in 2021, then soared by 113.12% to $309000.0 in 2022, then surged by 106.15% to $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then decreased by 4.0% to $96000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for TXMD at $96000.0 in Q3 2025, $96000.0 in Q2 2025, and $95000.0 in Q1 2025.